CORNELIUS, N.C. and NEW YORK, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Alpha Modus Corp. ("Alpha Modus" or the "Company”), a technology company with a core focus on artificial intelligence in retail, and Insight Acquisition Corp., a special purpose acquisition company ("Insight” NASDAQ: INAQ) plan to close their business combination today. Alpha Modus expects to begin trading on the Nasdaq Global Market under the ticker symbols "AMOD” (its common stock) and "AMODW” (its warrants) on Monday, December 16, 2024. About Alpha Modus Alpha Modus engages in creating, developing and licensing data-driven technologies to enhance consumers' in-store digital experience at the point of decision. The company was founded in 2014 and is headquartered in Cornelius, North Carolina. For additional information, please visit alphamodus.com. About Insight Acquisition Corp. Prior to the closing, Insight Acquisition Corp. (NASDAQ: INAQ) is a special purpose acquisition company formed solely to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. Insight Acquisition Corp. is sponsored by Insight Acquisition Sponsor LLC. For additional information, please visit insightacqcorp.com. Forward-Looking Statements This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Insight's and Alpha Modus' actual results may differ from their expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements, but are not the exclusive means of identifying these statements. These forward-looking statements include, without limitation, Insight's and Alpha Modus' expectations with respect to future performance and anticipated financial impacts of the Business Combination. Insight and Alpha Modus caution readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Insight and Alpha Modus do not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in their expectations or any change in events, conditions, or circumstances on which any such statement is based. Contacts: Alpha Modus Shannon Devine MZ Group +1(203) 741-8841 [email protected]Canopy Growth and Acreage Provide Update on Closing TimelineHerbert tosses 3 TD passes and Chargers secure a playoff spot with a 40-7 rout of Patriots
Biden says Assad's fall in Syria is a 'fundamental act of justice,' but 'a moment of risk'US lawmakers back Covid Chinese lab leak theory after two-year probe
– ENERGIZE-T Study Achieved Primary and All Key Secondary Endpoints in Adult Patients with Transfusion-Dependent Alpha- or Beta-Thalassemia – – ENERGIZE-T is First Phase 3 Study to Demonstrate Efficacy of an Oral, Disease-Modifying Treatment for Transfusion-Dependent Alpha- and Beta-Thalassemia – – Company Filed for Regulatory Approval of Mitapivat (PYRUKYND ® ) for the Treatment of Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia in U.S., European Union, Kingdom of Saudi Arabia and United Arab Emirates – – Live and Webcast Investor Event with Agios Leadership and Medical Experts will be Hosted in San Diego on Monday, December 9 at 7:00 a.m. PT – CAMBRIDGE, Mass., Dec. 08, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today presented positive results from the Phase 3 ENERGIZE-T study investigating mitapivat, an oral, small molecule PK activator, in adults with transfusion-dependent alpha- or beta-thalassemia. These findings were shared in an oral presentation (abstract #409) at the 66 th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, California. Thalassemia is a rare inherited blood disorder caused by genetic mutations that lead to a reduced production of healthy hemoglobin, compromising red blood cell development, health and survival, and resulting in chronic anemia. Patients with thalassemia often experience a range of debilitating complications, both from the disease itself and as secondary effects of common management strategies such as blood transfusions and iron chelation therapy, including organ damage, stroke, and other serious health issues. In the ENERGIZE-T trial, mitapivat demonstrated a statistically significant reduction in transfusion burden compared to placebo in patients with transfusion-dependent alpha- or beta-thalassemia, achieving its primary endpoint. Additionally, the ENERGIZE-T study met all the key secondary endpoints, with mitapivat demonstrating a statistically significant reduction in additional measures of transfusion reduction response compared to placebo. In June 2024, Agios also presented positive results from the Phase 3 ENERGIZE study, which evaluated mitapivat in adults with non-transfusion-dependent alpha- or beta-thalassemia. “Treatment options for patients with transfusion-dependent thalassemia are extremely limited, and transfusions carry serious risks, such as iron overload, infections and immune reactions. There is a significant need for alternative treatments to manage this debilitating disease,” said Maria Domenica Cappellini, M.D., professor, Internal Medicine, University of Milan, Italy. “The strong Phase 3 ENERGIZE-T results build on the positive findings from the Phase 3 ENERGIZE study in patients with non-transfusion-dependent alpha- or beta-thalassemia presented earlier this year, pointing to mitapivat as a potential transformative advancement in thalassemia care.” Phase 3 ENERGIZE-T Study Results ENERGIZE-T is a Phase 3, double-blind, randomized, placebo-controlled and multicenter 48-week study. A total of 258 patients were enrolled in the study worldwide, with 171 patients randomized to mitapivat 100 mg twice-daily (BID) and 87 patients randomized to matched placebo. The study’s primary endpoint of transfusion reduction response (TRR) was defined as a ≥50% reduction in transfused red blood cell (RBC) units with a reduction of ≥2 units of transfused RBCs in any consecutive 12-week period through Week 48 compared with baseline. A TRR was achieved by 30.4% (n=52/171) of patients in the mitapivat arm compared to 12.6% (n=11/87) of patients in the placebo arm (2-sided p=0.0003). Additionally, mitapivat demonstrated statistically significant reductions in transfusion burden compared with placebo as measured by the three key secondary endpoints of transfusion reduction response reflective of durability of response up to 36 weeks during the 48-week double-blind period. The key secondary endpoint TRR2, defined as a ≥50% reduction in transfused RBC units in any consecutive 24-week period through Week 48 compared with baseline, was achieved in 13.5% (n=23/171) versus 2.3% (n=2/87) of patients in the mitapivat and placebo arms, respectively (2-sided p=0.0003). The key secondary endpoints TRR3 and TRR4 were defined as a ≥33% and ≥50% reduction in transfused RBC units, respectively, from Week 13 through Week 48 compared with baseline. TRR3 was achieved in 14.6% (n=25/171) versus 1.1% (n=1/87) of patients in the mitapivat and placebo arms, respectively (2-sided pChicago Bulls guard Ayo Dosunmu has a strained right calf
NoneMore Aussies homeless as housing crisis worsensSports on TV for Sunday, Dec. 29
In an unforeseen move, Moody's has lowered France's credit rating, placing the nation at a significant fiscal crossroads. This adjustment elevates the pressure on France's newly appointed Prime Minister Francois Bayrou as he attempts to unify a fragmented government. Moody's decision, which aligns with those from Standard & Poor's and Fitch, signals concerns over France's budget management and comes after President Macron named Bayrou as the latest Prime Minister, the country's fourth this year. The political turmoil ensued after a thwarted attempt by former Prime Minister Michel Barnier to pass a contentious budget plan. The current fiscal landscape depicts a challenging road ahead for France, especially with Moody's projecting weaker public finances over the next three years. The downgrade has already impacted financial markets, with a notable increase in the risk premium on French government bonds. (With inputs from agencies.)UCF and Tulsa will test their mettle against each other on Saturday afternoon in the Orange Bowl Basketball Classic in Sunrise, Fla. The Knights will make their first appearance in the event since recording a two-point loss to Missouri in 2022, while Tulsa's last trip to the Orange Bowl Classic was a loss to Florida State in 2012. UCF (7-2) may have something to prove being away from Addition Financial Arena. The Knights are 7-0 at home, whereas a November trip to the Greenbrier Tip-Off in West Virginia produced an 86-70 loss to Wisconsin and a triple-overtime setback against LSU. The Knights relied heavily on their defense in Sunday's 66-51 win over Tarleton State. After a sluggish start offensively, UCF found its rhythm during a 37-point second half. Jordan Ivy-Curry finished with a game-high 16 points and freshman center Moustapha Thiam collected 10 points, nine rebounds and six blocks. UCF's Big 12 opener draws closer (at Texas Tech, Dec. 31), but head coach Johnny Dawkins remains focused on daily improvement. "I feel a sense of urgency to get better, not with regards to Big 12 play to be quite frank, but every game," Dawkins said. "I don't look too far in the future. Pretty much I've always been in the moment as a player and as a person, and so for me it's about just getting better because it's our standards." Tulsa (4-6) looks to stop a three-game slide following a 70-66 home loss to Southern University last Saturday. Keaston Willis scored in double figures for the sixth time this season, netting a season-high 23 points off the bench. But Isaiah Barnes, one of three Golden Hurricane players to start all 10 games, was injured in the first half and played only eight minutes. To complicate matters, head coach Eric Konkol's team is 0-6 when trailing at halftime. "We got to get some guys healthy that can be healthy for next Saturday (against UCF)," Konkol said. "We got a couple other guys dealing with some different things, but then (also) having some planning to figure out what's the best way going forward for this group." --Field Level Media
CHICAGO (AP) — Chicago Bulls guard Ayo Dosunmu has a strained right calf and will be reevaluated in 10 days. Dosunmu got hurt during Monday night’s 112-91 loss to Milwaukee. The Bulls provided an update on his injury on Saturday. Dosunmu, who turns 25 on Jan. 17, is averaging 12.6 points and 4.8 assists in his fourth NBA season. He has appeared in 30 games, including 17 starts. The Chicago native was selected by the Bulls in the second round of the 2021 draft. ___ AP NBA: https://apnews.com/hub/NBA
CARACAS (AFP) – Dozens of Venezuelans took to the streets in Caracas calling for the release of prisoners detained in protests against the disputed re-election of President Nicolas Maduro. “I’m tired of living in a country with such a dictatorship, I want to be free,” said one protester, who asked not to be named due to worries of being imprisoned herself. The rally was called by opposition politician Maria Corina Machado, who also urged the International Criminal Court – which is already investigating alleged crimes against humanity in Venezuela – to press for the release of what non-governmental organisation Foro Penal said are more than 1,900 “political prisoners”. Most of the detainees were arrested in protests that followed Maduro’s July election for a third consecutive six-year term, with his victory declared by state authorities seen as loyal to him. The opposition claimed the vote was fraudulent. Fearing arrest, Machado has been in hiding since the election, while opposition presidential candidate Edmundo Gonzalez Urrutia has fled to Spain.
Julián Álvarez picking up the scoring pace with Atletico MadridSome Dems frustrated